de Portu S - Search Results

1

Notification of undesirable effects of cosmetics and toiletries.

Sportiello L, Cammarota S, de Portu S, Sautebin L. Sportiello L, et al. Among authors: de portu s. Pharmacol Res. 2009 Feb;59(2):101-6. doi: 10.1016/j.phrs.2008.10.008. Epub 2008 Nov 6. Pharmacol Res. 2009. PMID: 19028583

2

Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.

de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG. de Portu S, et al. Clin Exp Hypertens. 2011;33(3):174-8. doi: 10.3109/10641963.2010.531846. Epub 2011 Apr 5. Clin Exp Hypertens. 2011. PMID: 21466388 Clinical Trial.

3

The pharmacoeconomic impact of amlodipine use on coronary artery disease.

De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani LG. De Portu S, et al. Pharmacol Res. 2006 Aug;54(2):158-63. doi: 10.1016/j.phrs.2006.04.002. Epub 2006 May 1. Pharmacol Res. 2006. PMID: 16814560

4

Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA.

Rossetti F, De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani LG. Rossetti F, et al. Among authors: de portu s. Pharmacol Res. 2006 Mar;53(3):197-201. doi: 10.1016/j.phrs.2005.10.002. Epub 2006 Jan 6. Pharmacol Res. 2006. PMID: 16406672

5

Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR--a study on safety, quality of life and economic impact.

Di Micco L, Torraca S, Pota A, Di Giuseppe D, Pisani A, Spinelli L, De Portu S, Sabbatini M, Mantovani L, Cianciaruso B. Di Micco L, et al. Among authors: de portu s. Nephrol Dial Transplant. 2009 Nov;24(11):3434-40. doi: 10.1093/ndt/gfp281. Epub 2009 Jun 16. Nephrol Dial Transplant. 2009. PMID: 19531671

6

Amlodipine: a pharmacoeconomic review.

de Portu S, Mantovani LG. de Portu S, et al. J Med Econ. 2009 Mar;12(1):60-8. doi: 10.3111/13696990802525266. J Med Econ. 2009. PMID: 19450066 Free article. Review.

7

Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.

de Portu S, Del Giglio M, Altomare G, Arcangeli F, Berardesca E, Calzavara-Pinton P, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA, Girolomoni G. de Portu S, et al. Dermatol Ther. 2010 Jan-Feb;23 Suppl 1:S7-13. doi: 10.1111/j.1529-8019.2009.01280.x. Dermatol Ther. 2010. PMID: 20136921

8

Cost-effectiveness analysis of bisoprolol treatment for heart failure.

Di Stasi F, Scalone L, De Portu S, Menditto E, Mantovani LG. Di Stasi F, et al. Among authors: de portu s. Ital Heart J. 2005 Dec;6(12):950-5. Ital Heart J. 2005. PMID: 16502708

9

Psoriatic arthritis: pharmacoeconomic considerations.

Olivieri I, Mantovani LG, D'Angelo S, Padula A, de Portu S. Olivieri I, et al. Among authors: de portu s. Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x. Curr Rheumatol Rep. 2009. PMID: 19691929

10

Oral antiviral therapies are cost-effective vs. no treatment but indirect comparisons should be avoided.

Mantovani LG, de Portu S. Mantovani LG, et al. Among authors: de portu s. J Hepatol. 2009 Dec;51(6):1086-7; author reply 1087-8. doi: 10.1016/j.jhep.2009.09.016. Epub 2009 Oct 7. J Hepatol. 2009. PMID: 19853949 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page